首页> 外文期刊>Radiation Oncology Journal >Therapeutic Results of Concurrent Chemoradiation in Locally Advanced Uterine Cervical Cancer
【24h】

Therapeutic Results of Concurrent Chemoradiation in Locally Advanced Uterine Cervical Cancer

机译:局部晚期宫颈癌同时放化疗的治疗结果

获取原文
           

摘要

PURPOSE: Despite a development fo therapeutic machines and advance in modern radiation therapy techniques, locally advanced cervical carcinoma has shown high rate of local failure and poor survival rate. Combination of chemotherapy and radiotherapy demonstrated benefit in improving local control and possibly the overall survival. Our study was performed to evaluate effect of concurrent chemoradiation on locally advanced uterine cervical cancer. METHODS AND MATERIALS: Twenty six patients with locally advanced stage(FIGO stage IIB with > or = 5 cm in diameter, III, IVA) were treated with combination of radiation therapy and concurrent cisplatinum between May of 1988 and Septermber of 1993 at our hopital. Radiation therapy consisted of external irradiation and 1-2 sessions of intracavitary irradiation, Cisplatinum was administered in bolus injection of 25mg/m(2) at weekly intervals during the course of external radiation therapy. RESULTS: Of the 26 patients, twenty-five patients were evaluable for estimation of response. Median follow-up period was 25 months with ranges from 3 to 73 months. Stage IIB, III, and IVA were 16, 5,4 patients, respectively. Twenty patients were squamous cell carcinoma. Response was noted in all 25 patients: complete response(CR) in 17/25(68%), partial response(PR) in 8/25(32%). Of the 24 patients except one who died of sepsis at 3 months follow-up, seventeen patients(70.8%) maintained local control in the pelvis: 16/17(94.1%) in CR, 1/17(14.3%) in PR. Fourteen of the 17 patients with CR are alive disease free on the completion of follow-up. Median survival is 28 months for CR and 15 months for PR. Analysis of 5-year survival by stage shows 11/16(59.8) in IIB, 3/5(60.6%) in III, and 1/4(25.0%) in IVA. Overall 5-year survival rate was 55.2%. Ten Patients recurred: 4 at locoegional,3 in distant metastasis and 3 with locoregional and distant site. Toxicity by addition of cisplatinum was not excessive. CONCLUSION: Although the result of this study was obtained from small number of patients, it is rather encouraging in view of markedly improved response rate compared with the results of historical group.
机译:目的:尽管治疗机有所发展,现代放射治疗技术也有所进步,但局部晚期宫颈癌的局部衰竭率高,生存率低。化学疗法和放射疗法的结合在改善局部控制和可能的总体生存方面显示出益处。我们的研究旨在评估同时放化疗对局部晚期宫颈癌的影响。方法和材料:1988年5月至1993年9月在我院接受放疗和同期顺铂联合治疗的26例局部晚期阶段(FIGO直径大于或等于5 cm的IIB期,III,IVA)患者。放射治疗包括外部照射和1-2次腔内照射,在外部放射治疗过程中,以每周间隔25mg / m(2)推注顺铂。结果:在这26例患者中,有25例患者可以评估反应的评估。中位随访期为25个月,范围为3到73个月。 IIB,III和IVA期分别为16、5、4名患者。 20例为鳞状细胞癌。在所有25例患者中均注意到缓解:完全缓解(CR)占17/25(68%),部分缓解(PR)占8/25(32%)。除了一名在3个月的随访中死于败血症的患者外,这24例患者中有17例(70.8%)保持骨盆局部控制:CR为16/17(94.1%),PR为1/17(14.3%)。 17例CR患者中的14例在随访完成时无生命疾病。 CR的中位生存期为28个月,PR的中位生存期为15个月。按阶段分析的5年生存率显示,IIB为11/16(59.8),III为3/5(60.6%),IVA为1/4(25.0%)。总体5年生存率为55.2%。复发10例:局部发生4例,远处转移3例,局部区域和远处3例。加入顺铂的毒性并不过度。结论:尽管这项研究的结果是从少数患者中获得的,但与历史组的结果相比,由于显着提高了反应率,这是令人鼓舞的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号